Pfizer recently called for the emergency use of its coronavirus vaccine in India.
New Delhi. U.S. pharmaceutical company Pfizer recently called for the emergency use of its coronavirus vaccine in India, requiring its dose of vaccine to be stored at minus 70 degrees Celsius. The company has revealed that it is working on a new formulation that will not need to be stored at extreme temperatures and can be stored in simple refrigeration. The vaccine based on Pfizer’s mRNA technology is more than 90% effective with double doses and 67% with one dose. But it does require a temperature of minus 70 degrees Celsius, and cold storage facilities in India don’t have such a low temperature.
Clarifying the matter, Pfizer CEO Albert Borla told a press conference hosted by the International Federation of Pharmaceutical Manufacturers and Associations: “We are working on a new formulation that does not need to be stored at minus 70 degrees. Hoagie and can be stored in simple refrigeration. “
However, he stressed that the company is still confident in its ability to deliver products at minus 70 degrees Celsius. In addition, he prepared a detailed logistics plan for vaccine storage, temperature monitoring and vaccine transport.
The multinational biopharmaceutical company applied for approval for the emergency use of its vaccine in India on December 6 after being cleared in the UK and Bahrain. On Tuesday, the Union Health Ministry reported that 8 Kovid-19 vaccine candidates are in various stages of clinical trials, which may be ready for authorization soon. In addition to Pfizer, Bharat Biotech and Serum Institute of India recently called for emergency use of their vaccine.